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Abstract Apolipoprotein E (apoE) has been found in association 
with several differents types of systemic and cerebral amyloid 
deposits and the presence of the E4 allele constitutes a risk factor 
for Alzheimer's disease. It has been shown that apoE binds and 
promotes the fibrillogenesis in vitro of Alzheimer's amyloid l[I- 
peptide, suggesting an important role for apoE in the modulation 
of amyloidogenesis. Due to the co-localization of apoE with sev- 
eral biochemically distinct amyloid deposits, it has been proposed 
that apoE plays a general role modulating and/or participating 
in amyloidosis. In the present study, we show for the first time 
that apoE, isolated from human plasma, increases fibril formation 
of synthetic peptides comprising the amyloidogenic sequences of 
gelsolin amyloid related to familial amyloidosis Finnish type, and 
amyloid A found in secondary amyloidosis and familial Mediter- 
ranean fever. Our results suggest that apoE acts as a general 
pathological chaperone in various amyloidoses by enhancing the 
transition from soluble peptides into amyloid-forming, pathologi- 
cal molecules. 
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1. Introduction 
Amyloidosis is a common feature among many different 
diseases in which proteins are deposited in the extracellular 
space of different issues in the form of amyloid fibers [review 
1]. Although amyloid proteins contain different amino acid 
sequences they all adopt a t-pleated structure in their fibrillar 
state. Amyloid fibrils are characteristically 8-10 nm wide, un- 
branched filaments which share common tinctorial properties, 
including reen birefringence after staining with Congo red and 
binding to the fluorescent dyes thioflavine S and T. Most amy- 
loid proteins how amino- and carboxy-terminal heterogenicity 
and point mutations have been described in hereditary forms 
of the amyloid iseases. Although amyloid deposits are believed 
to be formed by the polymerization f a single protein, certain 
amyloid associated proteins often are found co-localized in 
these deposits. Among these amyloid associated proteins, amy- 
loid P-component [2], proteoglycans [3,4], cq-antichymotrypsin 
[5], apolipoprotein E (apoE) [6,7] and apolipoprotein J [8,9] 
appear to be the most abundant. Whether these amyloid asso- 
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ciated proteins play an active role in amyloidogenesis or are 
inert bystanders i at present unclear. 
Apolipoprotein E (ApoE) is a 299 amino acid long protein 
with a molecular weight of 34 kDa, associated with lipid trans- 
port [10]. The ApoE gene, located on chromosome 19, has been 
associated with sporadic and late-onset Alzheimer's disease 
(AD) [11], a disorder characterized by the massive deposition 
ofa 4.3-kDa amyloid fl-peptide (Aft) in the brain [12,13]. It has 
been demonstrated that the inheritance of the e4 allele consti- 
tutes a risk factor for AD, modulates the age of onset of the 
disease and correlates with a greater amount of Aft deposition 
in the brain [11,14,15]. The biochemical mechanism to explain 
the genetic association of apoE4 with AD is, however, unclear. 
Immunohistochemical studies have shown that apoE is present 
in a wide variety of systemic and cerebral amyloid eposits [6,7], 
including secondary amyloidosis and familial Mediterranean 
fever related to amyloid A (AA), immunoglobulin-related pri- 
mary amyloidosis, familial amyloidotic polyneuropathy with 
transthyretin deposition, cystatin C-related hereditary cerebral 
amyloid angiopathy of Icelandic type, familial amyloidosis of 
Finnish type (FAF) and spongiform encephalopathies, such as 
Creutzfeld-Jakob disease, kuru and Gerstmann-Straussler- 
Scheinker disease. 
The wide association of apoE with clinically and biochemi- 
cally distinct ypes of amyloidoses has led to the proposal that 
apoE may have an important general role in amyloidogenesis. 
This can be the promotion of fibril formation, possibly by 
inducing t-pleated sheet conformation i  amyloidogenic pep- 
tides [7]. In this study, we have analysed the effect of apoE on 
amyloid fibril formation by synthetic peptides containing amy- 
loidogenic sequences of the gelsolin derived amyloid fragment 
and amyloid A as compared with the effect of apoE on Alz- 
heimer's Aft peptide. 
2. Materials and methods 
2.1. Synthetic peptides and proteins 
The following synthetic peptides were used (Fig. 1): Afll-40 contain- 
ing the sequence 1~,0 of Aft; Afll-40Q bearing the substitution Gln (Q) 
for Glu (E) at position 22, homologous tothe Dutch variant of Aft [16]; 
Afll-16 used as a control non-fibrillogenic analog of Aft; AGeI,~, con- 
taining the sequence 183-197 of human gelsolin; AGely containing the 
same sequence but bearing the substitution ofTyr (Y) for Asp (D) at 
position 187, found in some cases of FAF; AGel N containing the substi- 
tution Asn (N) for Asp (D) at position 187; Ge1165-182 used as a
non-fibrillogenic control; AA15 corresponding to the sequence 1-15 
and AA14 containing the sequence 2-15 of human AA amyloid, respec- 
tively. Aft and AA peptides were synthesized at theW.M. Keck Facility, 
University of Yale, by solid phase technique. Afll-16 was obtained 
from Sigma (St. Louis, MO). AGel peptides were purchased from 
BioSynthesis (Lewisville, TX). All peptides were purified by microbore 
reverse phase high-performance liquid chromatography (HPLC). The 
purity of each peptide was evaluated byamino acid composition anal- 
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ysis and laser desorption mass spectrometry. Stock solutions of each 
peptide were prepared in 50% acetonitrile and the final concentration 
determined by amino acid composition analysis on a Waters Accu-Tag 
amino acid analyser. 
Human plasma apoE was purchased from Calbiochem (LaJolla, 
CA). Its purity (>95%) was verified by SDS-PAGE and N-terminal 
sequence analysis. Stock solutions were made in 0.1 M Tris-HCl, 
pH 7.4, and quantitated with the Coomassie plus protein assay kit 
(Pierce). 
2.2. Fluorometric assay 
Aliquots of peptides were lyophilized, resuspended in 0.1 M Tris- 
HC1, pH 7.4, and incubated for different imes at room temperature. 
For coincubation experiments, aliquots of apoE to a final molar ratio 
peptide:apoE of 100:1 were added. Amyloid fibril formation was 
quantitated by the thioflavine T (ThT) method, as previously described 
[17]. Briefly, pre-incubated samples were added to 50 mM glycine, 
pH 9.2, 2/JM ThT to a final volume of 2 ml. Fluorescence was measured 
at excitation 435 nm and emission 485 nm using a Hitachi F-2000 
fluorescence spectrometer. A time scan of fluorescence was performed 
and three values after the decay reached the plateau (around 300 s) were 
averaged after substracting the background fluorescence of2/tM ThT. 
All the experiments were performed in triplicate. 
2.3. Electron microscopy 
Peptides (1 mg/ml) were incubated with or without apoE in 0.1 M 
Tris-HC1, pH 7.4, for 5 days at room temperature. Aliquots of each 
sample were then spotted on a carbon formvar-coated 400-mesh nickel 
grids for 1 min, washed with distilled water and stained for 90 s with 
2% uranyl acetate. Grids were visualized on a Zeiss EM 10 electron 
microscope at 80 kV. 
2.4. Sedimentation assay 
Peptides were incubated in 0.1 M Tris-HC1, pH 7.4, for different 
times at room temperature. To separate the soluble and aggregated 
peptide, each sample was centrifuged at 14,000 rpm for 15 min in an 
Eppendorf microfuge. Aliquots of the supernatant were analysed by 
microbore HPLC using a reverse phase Vydac C4 column (214 TP 52) 
and a linear gradient of 3-70% acetonitrile in 0.1% TFA in 25 min. 
Absorbance was monitored at 220 nm. The percentage of the non- 
sedimentable p ptide was measured by comparing the area of the peak 
corresponding to the soluble peptide at diferent imes of incubation 
with that obtained with the non-incubated sample. 
3. Results and discussion 
All synthetic peptides modeled on the amyloidogenic se- 
Table 1 
Effect of human plasma apoE on amyloid formation by Agel, AA and 
Aft analogs 
Peptide ThT-ftuorescence apoE b 
enhancement Peptide alone Peptide with apoE 
AGe1183-197 wr 3.6 + 0.2 7.7 + 0.4 2.14 
AGe1183-197 v 1.6 + 0.3 13.9 _+2.3 8.69 
AGel183-197 TM 17.6 + 1.9 22.2 + 2.2 1.26 
Ge1165-182 0.53 + 0.1 0.58 + 0.05 1.09 
AA14 2.9 + 0.6 16.9 + 3.7 5.83 
AA15 14.1 + 0.7 14.3 + 1.5 1.01 
Afll-40 a 15.2 + 1.1 33.8 + 2.9 2.22 
Afll~J,0Q a 33.8 + 0.4 38.1 + 2.5 1.13 
Afll-16 0.39 + 0.04 0.34 + 0.07 0.87 
30-pg aliquots of the peptides were incubated with or without apoE in 
a molar ratio I : 100 in 30/11 of 0.1 M Tris, pH 7.4, for 24 h. Amyloid 
formation was quantitated by ThT-fluorescence in triplicate. ApoE 
alone did not produce any fluorescence above the background. 
aThe effect ofapoE on the amyloid formation by At i l t0  and Af l l~0Q 
was already published as part of a previous paper [28]. 
bApoE enhancement correspond to the increment of amyloid formed 
by the peptides incubated with apoE as was calculated by dividing the 
fluorescence values obtained in the presence and in the absence of apoE. 
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Fig. 1. Schematic representation f the amyloid precursor proteins, the 
fragments deposited as amyloid in the tissues and the synthetic peptides 
used as a model in the present study. (A) Alzheimer's fl-amyloid, (B) 
Gelsolin amyloid and (C) AA amyloid. The black box represents he 
peptide fragment most commonly deposited as amyloid in the tissues. 
In the case of the Alzheimer's fl-amyloid precursor protein and serum 
amyloid A protein, only one isoform is represented. 
quence of Aft (Fig. 1A), AGel (Fig. 1B) and AA (Fig. 1B) were 
able to produce amyloid-like fibrils with morphological charac- 
teristics typical of amyloid (Fig. 2). The fluorometric assay was 
used to measure the effect of apoE on amyloid fibril formation 
by these synthetic peptides. At a molar ratio of 1:100 
(apoE: peptide), human plasma apoE clearly promotes amyloid 
formation of all the amyloidogenic peptides, as shown in 
Table 1. This molar ratio was used in order to mimic the condi- 
tions locally occuring in amyloid, considering the yield of apoE 
fragments extracted from brain and systemic amyloid deposits 
[18,19]. The effect of apoE was maximal up to 24 h after which 
only a small amount of additional amyloid could be detected. 
Interestingly, the promoting effect of apoE was higher in those 
peptides which were less amyloidogenic (AGely, A t i l t0  and 
AA14) and lower in those peptides that were more amy- 
loidogenic (AGelN, Af l l -40Q and AA15) (Table 1). These re- 
sults suggest hat apoE promotes amyloidogenesis by enhanc- 
ing the fibrillogenic potential of peptides less able to form 
amyloid. Electron microscopic examination of the incubated 
samples showed that morphologically similar amyloid-like fi- 
brils were formed by the amyloidogenic peptides in the presence 
or absence of apoE (data not shown). 
In order to quantitate the level of peptide aggregation, we 
measured the amount of remaining soluble peptide after differ- 
ent times of incubation by the sedimentation assay (Fig. 3). 
Each peptide aggregated only partially in the absence of apoE, 
even after long incubation times (> 120 h) (Fig. 3). The excep- 
tion was AA15 which sedimented almost completely after 
112 C. Soto et aI. IFEBS Letters 371 (1995) 110-114 
Fig. 2. Electron micrographs of negatively stained amyloid-like fibrils 
produced in vitro bysynthetic peptides containing the amyloidogenic 
sequence of Aft, AGel and AA. Aliquots of peptides at 1 mg/ml were 
incubated for 5 days at room temperature and the fibrils were visualized 
as described in Section 2. (a) Afll-40; (b) Afll~0Q; (c) AA14; (d) 
AA15; (e) Agelwt; (f) AGely; (g) AGelN. The peptides used as controls 
(Afll-16 and Gel165 182) did not produce amyloid-like fibrils. The 
scale bar represents 100 nm. 
5 days of incubation. Addition of apoE to the remaining super- 
natant of AGelwt, Aft 1-40 and AA 14 after 6 days of incubation, 
reinitiated precipitation (Fig. 3). The control peptides (Afll-16 
and Gel165 182) remained 100% soluble after times longer 
than 6 days and were not affected by apoE. One xplanation 
of our findings is that apoE decreases the critical concentration 
of aggregation, i.e., the minimum concentration essential for 
peptide interaction, by favoring the intermonomeric associa- 
tion to give rise to amyloid. Alternatively the results can be due 
to the transformation by apoE of some soluble non-amy- 
loidogenic peptides to a state capable of ordered aggregation. 
If the fibrillogenesis promotion by apoE is due to the induction 
of a decrease in the critical concentration for aggregation, this 
effect should be mimicked by concentration of remaining solu- 
ble sample. 
In order to test these two alternatives, we concentrated the 
peptide fraction remaining soluble after 6 days of incubation 
of AGelwt, AA14 and Afll-40 to 2 mg/ml and continued the 
incubation. Each peptide remained soluble even after several 
days of incubation in the absence of apoE, but they rapidly 
aggregated in the presence of apoE (data not shown). These 
results suggest that apoE promotes fibrillogenesis by changing 
the conformation of soluble peptides, incompetent to form am- 
yloid fibrils, to a state which they rapidly form amyloid like 
aggregates. 
Synthetic peptides homologous to proteins or peptides frag- 
ments isolated from amyloid deposits, have been extensively 
used as a model to study fibril formation in vitro. It has been 
shown that the complete sequence 1-40 or 1-42 of Aft (Fig. 1A) 
and also shorter derivatives thereof can form amyloid-like fi- 
brils in vitro exhibiting afl-pleated sheet conformation, similar 
to that found in Alzheimer's amyloid plaques (for a review, see 
[20]). Similarly, synthetic peptides containing a part of the se- 
quence of gelsolin derived amyloid fragment with the substitu- 
tions Asp to Asn or Tyr at position 187 form ultrastructurally 
amyloid-like fibrils in vitro [21]. The shortest gelsolin peptide 
capable of forming amyloid-like fibrils was reported to be a 9 
amino acid long fragment corresponding to the sequence 183- 
191 [21]. In secondary or reactive amyloidosis, protein AA 
fragments have been isolated from amyloid deposits associated 
with chronic infections, inflamatory disorders and certain neo- 
plasms [22,23]. AA amyloid corresponds to the N-terminal 
fragment formed by cleavage and removal of the C-terminal 
part of a larger precursor protein, called serum amyloid A (Fig. 
1C). It has been shown that several peptides containing a part 
of the N-terminal fragment of serum amyloid A can form am- 
yloid-like fibrils in vitro [24]. The shortest fragment reported 
to form amyloid-like fibrils corresponds to a 13 residue long 
peptide with the sequence 2-12 of AA [24]. 
ApoE is a ubiquitous protein, associated with several types 
of cerebral and systemic amyloidoses [6,7]. It has been pro- 
posed that apoE acts as a pathological molecular chaperone i  
disorders in which amyloid material is accumulated. Pathologi- 
cal chaperones are defined as proteins mediating fl-pleated am- 
yloid formation of polypeptide fragments [7]. Recently, it has 
been shown that apoE binds to Aft [14,25], promotes Aft amy- 
loid formation in vitro [2628] and induces conformational 
changes in Aft to give rise to the amyloidogenic fl-sheet confor- 
mation of this peptide (Soto et al., in prep.). Our present find- 
ings show for the first time that apoE can also enhance the 
fibrillogenesis of other amyloid-related peptides, suggesting 
that the effect of apoE is not specific for amyloid formation by 
Aft, but rather reflects the general ability of apoE to stabilize 
or induce fl-sheet structure in peptides bearing the potential to 
adopt this conformation. Our data indicate that apoE has a 
general role in amyloidogenesis by acting as a universal pa- 
thological chaperone, binding hydrophobically to a common 
conformation shared by different amyloid peptides, regardless 
of their amino acid sequence. Recently, it has been shown that 
the carboxyl-terminal domain of apoE copurifies with AD se- 
nile plaques [18] and with amyloid deposits derived from amy- 
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Fig. 3. Percentage of soluble peptide after different incubation times 
and effect of apoE. 100/~g of synthetic peptides containing the amy- 
loidogenic sequence of gelsolin (A), Aft (B) and AA (C) amyloids were 
incubated in 50/11 of 0.1 M Tris, pH 7.4, at room temperature. At the 
indicated times, the samples were c ntrifuged at14,000 rpm for 15 min 
and 3/11 of the supernatant was subjected to reverse phase HPLC. The 
percentage of the soluble peptide was determined asdescribed in Sec- 
tion 2. Arrow indicates when an appropiate amount of apoE to get a 
final molar ratio (apoE:peptide) 1 : 100, was added to the solution. 
loid A and amyloid L [19]. Moreover, the C-terminal fragment 
of apoE can form amyloid-like fibrils in vitro [18], leading to 
the idea that, when an amyloid-associated protein is misfolded, 
it can propagate his misfolding by acting as a template for 
another protein that does not share amino acid sequence ho- 
mology [29]. This conformational mimicry may explain the 
effect of apoE upon various sequentially unidentical amyloid 
peptides. 
In this study we used pooled apoE isolated from human 
plasma, which contains a mixture of the three isoforms, but 
according to the statistical distribution of apoE isoforms in the 
population, corresponds mainly to the isoform apoE3. The 
human plasma apoE was used since it has been reported that 
there is no association between e alleles and systemic amyloid 
disorders and that recombinant apoE isoforms are less active 
than native pooled apoE [28]. The genetical association of 
apoE4 to some amyloid diseases might be a consequence of a 
more complicated cascade of events rather than a direct pro- 
tein-protein interaction. Alternatively, it is possible than cer- 
tain apoE isoforms are more efficient promoters of amyloid 
formation by some amyloidogenic peptides than others, as 
apoE4 appears to be the most effective promotor of Aft fibril- 
logenesis in vitro [26,27]. 
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